Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials.
from The Medical News http://ift.tt/1blpzp8
from The Medical News http://ift.tt/1blpzp8
No comments:
Post a Comment